Sulfonated Polystyrene Derivatives for Specialized Feline Health Applications

Publication ID: 24-11857566_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Sulfonated Polystyrene Derivatives for Specialized Feline Health Applications,” Published Technical Disclosure No. 24-11857566_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857566_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,566.

Summary of the Inventive Concept

The inventive concept adapts sulfonated polystyrene derivatives for treating and preventing feline diseases in unique operational environments, including high-altitude, high-security, extreme weather, disaster relief, and high-air-pollution settings.

Background and Problem Solved

The original patent discloses sulfonated polystyrene derivatives for treating and preventing cat flu. However, the original patent does not address the specific challenges posed by treating feline diseases in specialized environments, such as high-altitude, high-security, extreme weather, disaster relief, and high-air-pollution settings. The new inventive concept solves this problem by adapting the sulfonated polystyrene derivatives to withstand and mitigate the effects of these unique environments.

Detailed Description of the Inventive Concept

The inventive concept comprises sulfonated polystyrene derivatives formulated to address the specific challenges of treating feline diseases in high-altitude, high-security, extreme weather, disaster relief, and high-air-pollution settings. For example, the derivatives may be adapted to withstand extreme temperatures, high humidity, or air pollution. The derivatives may also be formulated to be used in high-security environments, such as animal shelters, or in disaster relief situations, where the availability of medical resources may be limited. The inventive concept also includes systems, methods, compositions, and kits for treating and preventing feline diseases in these unique operational environments.

Novelty and Inventive Step

The new claims introduce novel and non-obvious adaptations of sulfonated polystyrene derivatives for treating and preventing feline diseases in specialized environments. The inventive concept's formulation and adaptation of the derivatives to withstand and mitigate the effects of these unique environments constitute a significant inventive step over the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include sulfonated polystyrene derivatives adapted for use in other unique operational environments, such as space exploration or remote wilderness areas. Variations of the inventive concept may include the use of different types of sulfonated polystyrene derivatives or different formulations tailored to specific environmental challenges.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the veterinary pharmaceutical industry, particularly in the areas of feline health and disease prevention. The target market includes veterinarians, animal shelters, and pet owners who require effective treatments for feline diseases in specialized environments.

Field of Art

Veterinary pharmaceuticals, specifically feline viral disease treatment and prevention, with expertise in polymer chemistry and drug formulation for animal health applications

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degree in veterinary medicine or pharmaceutical sciences, understanding polymer chemistry, viral disease mechanisms, and drug delivery systems for animal health

Obviousness Rationale

A PHOSITA would recognize that sulfonated polystyrene derivatives can be readily adapted for different environmental conditions by modifying excipients, delivery mechanisms, and formulation parameters. The core therapeutic mechanism of treating feline viral infections remains consistent across the disclosed variations. The adaptations represent predictable engineering solutions to extend the original patent's core invention to specialized use contexts.

Obvious Combinations & Variations

Source Patent Element
Sulfonated polystyrene derivative for treating cat flu
PTD Variation
Formulating derivative for high-altitude or extreme temperature environments
Obviousness Reasoning
Modifying pharmaceutical formulations for environmental resilience is a standard design approach known to those skilled in drug delivery, representing a predictable variation
Source Patent Element
Method of treating feline calicivirus
PTD Variation
Adapting delivery for high-security animal shelter environments
Obviousness Reasoning
Adjusting pharmaceutical administration protocols for specific institutional settings is a routine optimization process for veterinary medications
Source Patent Element
Sodium polystyrene sulfonate for viral treatment
PTD Variation
Adding temperature-resistant excipients for extreme condition stability
Obviousness Reasoning
Incorporating stabilizing agents to enhance drug performance is a well-established pharmaceutical engineering technique with predictable outcomes
Source Patent Element
Feline herpesvirus treatment method
PTD Variation
Creating specialized delivery kit for disaster relief scenarios
Obviousness Reasoning
Developing context-specific medical kits is a standard approach for extending pharmaceutical utility to challenging environments
Source Patent Element
Polystyrene derivative for viral prophylaxis
PTD Variation
Formulating medication to mitigate air pollution exposure effects
Obviousness Reasoning
Adapting pharmaceutical compositions to address environmental interaction challenges represents a predictable engineering solution within pharmaceutical development
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed herein would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the core therapeutic method disclosed in US Patent 11857566, involving routine pharmaceutical engineering adaptations to specialized environmental contexts without introducing inventive complexity.

Original Patent Information

Patent NumberUS 11,857,566
TitleSulfonated polystyrene derivative for use in the treatment and/or prophylaxis of cat flu
Assignee(s)UNIWERSYTET JAGIELLONSKI